Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids

Arthritis and Rheumatism

Volumn 42, Issue 8, 1999, Pages 1601-1608

  Leech, Michelle ^a   Metz, Christine ^b   Hall, Pamela ^a   Hutchinson, Paul ^a   Gianis, Katerina ^a   Smith, Malcolm ^c   Weedon, Helen ^c   Holdsworth, Stephen R ^a   Bucala, Richard ^b   Morand, Eric F ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b PICOWER INST FOR MEDICAL RESEARCH   (United States)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

AGED; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; GLUCOCORTICOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033509041     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B     Document Type: Article

References (42)

1. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognised source of macrophage migration inhibitory factor. J Exp Med 1994;179: 1895-902.
2. Bacher M, Metz CN, Calandra T, Mayer K, Cheney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 1996;93:7489-854.
3. Churchill WH, Piessens WF, Sulis CA, David JR. Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol 1975;115: 781-6.
4. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Pathology 1966;56:72-7.
5. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994;33:14144-55.
6. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997;40:1050-3.
7. Liew FY. Regulation of nitric oxide synthesis in infectious and autoimmune diseases. Immunol Lett 1994;43:95-8.
8. Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira A. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in an autocrine and paracrine fashion. Immunology 1997;92:131-7.
9. Juttner S, Bernhagen J, Metz CN, Rollinghoff M, Bucala R, Gessner A. Migration inhibitory factor induces killing of leishmania major by macrophages; dependence on reactive nitrogen intermediates and endogenous TNF-α. J Immunol 1998;161:2383-90.
10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71.
11. Calandra T, Bucala R. Macrophage migration inhibitory factor - a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 1996;47:39-51.
12. Bernhagen J, Bacher M, Calandra T, Metz CN, Doty SB, Donelly T, et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity response. J Exp Med 1996;183:277-82.
13. Leech M, Metz C, Santos L, Peng T, Holdsworth SR, Bucala R, et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998;41:910-7.
14. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type-II induced arthritis in mice. J Immunol 1997;158: 5514-7.
15. Burmester GR, Stuhlmüller B, Keyszer G, Kinne RW. Mono-nuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5-18.
16. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
17. Grabowski PS, Macpherson H, Ralston SH. Nitric oxide production in cells derived from the human joint. Br J Rheumatol 1996;35:207-12.
18. Santos LL, Morand EF, Holdsworth SR. Suppression of adjuvant arthritis by N-iminoethyl-l-ornithine, a nitric oxide synthase inhibitor. Inflammation 1997;21:299-311.
19. Sternberg EM, Young WS III, Bernardini R, Calogero AE, Chrousos GP, Gold PW, et al. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci U S A 1989;86:4771-5.
20. Harbuz MS, Rees RG, Lightman SL. HPA axis responses to acute stress and adrenalectomy during adjuvant-induced arthritis in the rat. Am J Physiol 1993;264:R179-85.
21. Mason D, MacPhee I, Antoni F. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. J Immunol 1990;70:1-5.
22. Flower RJ, Parente L, Persico P, Salmon JA. A comparison of the acute inflammatory response in adrenalectomised and sham-operated rats. Br J Pharmacol 1986;87:57-62.
23. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanic KS, et al. Circadian relationship between IL-6 and hypothalamus-pituitary-adrenocortical axis hormones: failure of IL-6 to cause hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279-83.
24. Grudbj-Ornsson B, Skogseid B, Oberg B, Wilde L, Hallgren R. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis: effect of glucocorticoids. J Rheumatol 1996;23:596-602.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Ma W, Pober JS. Human endothelial cells effectively co-stimulate cytokine production by, but not differentiation of, naive CD4+ T cells. J Immunol 1998;161:2158-67.
27. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998;10: 199-205.
28. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
29. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WAH, Metz CN, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997;3: 320-3.
30. Seki T, Selby J, Häupl T, Winchester R. Use of a differential subtraction method to identify genes that characterize the phenotype of cultured rheumatoid arthritis synoviocytes. Arthritis Rheum 1998;41:1356-64.
31. Zvaifler NJ, Firestein GS. Pannus and pannocytes: alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
32. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Nilson-Hamilton M, Hamilton RT. Expression of the collagenolytic and ras-induced cysteine proteinase cathepsin-L and proliferation associated oncogenes in synovial cells of MRL/1 mice and patients with rheumatoid arthritis. Matrix Biol 1990;10:349-61.
33. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997;94: 10895-900.
34. Bloom BR, Bennet B. Mechanism of a reaction in vitro associated with delayed type hypersensitivity. Science 1966;153:80-2.
35. Nathan CF, Remold HG, David JR. Characterisation of a lymphocyte factor which alters macrophage functions. J Exp Med 1973;137:275-89.
36. Keyszer G, Heer AH, Gay S. Cytokines and oncogenes in cellular interactions in rheumatoid arthritis. Stem 1994;12:75-86.
37. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
38. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
39. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of pro-inflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of anti-TNFα antibody with the IL-1 receptor antagonist. Eur Cytokine Netw 1995;6:225-30.
40. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
41. Munck A, Naray-Fejes-Toth A. The ups and downs of glucocorticoid physiology - permissive and suppressive effects revisited. Mol Cell Endocrinol 1992;90:C1-4.
42. Wiegers G, Croiset G, Reul J, Holsboer F, De Kloet E. Differential effects of corticosteroids on rat peripheral blood T-lymphocyte mitogenesis in vivo and in vitro. Am J Physiol 1993;28:E825-30.